Puma Biotechnology (NASDAQ:PBYI)‘s stock had its “buy” rating restated by equities researchers at Citigroup Inc. in a research report issued on Tuesday. They currently have a $99.00 price target on the stock, down from their previous price target of $123.00. Citigroup Inc.’s target price points to a potential upside of 59.27% from the company’s current price.
Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 62.16 on Tuesday. Puma Biotechnology has a 52 week low of $33.70 and a 52 week high of $143.65. The stock has a 50-day moving average of $64.14 and a 200-day moving average of $94.93. The company’s market cap is $1.872 billion.
Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Monday, May 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.19. On average, analysts predict that Puma Biotechnology will post $-2.56 earnings per share for the current fiscal year.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.